BACKGROUND: Risk stratification is a major challenge in bladder cancer (BC), and a biomarker is needed. Multiple studies have reported the neutrophil-to-lymphocyte ratio (NLR) as a promising candidate; however, these analyses have methodological limitations. Therefore, the authors performed a category B biomarker study to test whether NLR is prognostic for overall survival (OS) after curative treatment or is predictive for the survival benefit from neoadjuvant chemotherapy (NAC). METHODS: This study is an unplanned secondary analysis of SWOG 8710, a randomized phase 3 trial that assessed cystectomy with or without NAC in 317 patients with muscle-invasive BC. NLR was calculated from prospectively collected complete blood counts. For the prognostic analysis, 230 patients were identified; for the predictive analysis, 263 were identified. NLR was evaluated with proportional hazards models including prespecified factors (age, sex, T-stage, lymphovascular invasion, and treatment arm). RESULTS: With a median follow-up of 18.6 years, there were 172 and 205 deaths in the prognostic and predictive cohorts, respectively. In a multivariable analysis, NLR was not prognostic for OS (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.98-1.11; P 5.24). Furthermore, NLR did not predict for the OS benefit from NAC (HR, 1.01; 95% CI, 0.90-1.14; P 5.86). Factors associated with worse OS were older age (HR, 1.05; 95% CI, 1.04-1.07; P <.001) and surgery without NAC (HR, 1.39; 95% CI, 1.03-1.88; P 5.03). CONCLUSIONS: This is the first analysis of NLR in BC to use prospectively collected clinical trial data. In contrast to previous studies, it suggests that NLR is neither a prognostic nor predictive biomarker for OS in muscle-invasive BC. Cancer 2017;123:794-801.
INTRODUCTION
Preoperative risk stratification is a major challenge in bladder cancer (BC), 1, 2 and a robust biomarker is needed. [3] [4] [5] One emerging candidate is the neutrophil-to-lymphocyte ratio (NLR). NLR is easily calculated from a complete blood count (CBC) and is felt to reflect the systemic inflammatory state. [6] [7] [8] [9] [10] A high ratio may be linked to cancer progression through increased pro-growth and pro-angiogenic factors 9, 10 coupled with decreased lymphocyte-mediated tumor surveillance. 11 In clinical studies, an elevated NLR correlates with inferior survival in many solid malignancies. [6] [7] [8] Specifically in BC, previous reports suggest NLR holds prognostic value. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] For example, an elevated pretreatment NLR has been associated with worse survival after radical cystectomy (RC). [12] [13] [14] [15] [16] Other studies have linked NLR with a higher burden of disease at surgery (eg, muscle-invasiveness, [17] [18] [19] extravesical extension, [13] [14] [15] 20 and node positivity 14 ) ; this raises the possibility that, in addition to being a prognostic biomarker, NLR might also predict which patients will benefit from neoadjuvant chemotherapy (NAC). 25 If validated, NLR would be an inexpensive, widely available, and appealing biomarker for BC.
However, results from previous studies are threatened by methodological limitations. These include the use of observational data sets and dichotomization of the NLR variable. Considerably stronger evidence would be generated by rigorously analyzing prospectively collected biomarker specimens from a clinical trial [26] [27] [28] -a category B study per the biomarker evidence framework of Simon et al. 28 SWOG 8710 is well-suited for such an investigation. This randomized phase 3 trial tested RC with or without NAC for muscle-invasive BC. 29 It offers several notable advantages for an analysis of NLR. First, CBCs were prospectively collected at baseline per protocol. Second, the trial's significant long-term follow-up captured enough events to generate adequate statistical power. 28 Third, in addition to prognostic value, NLR's predictive value can also be assessed because of the randomization to NAC.
Therefore, we used SWOG 8710 to evaluate NLR in BC. Specifically, we tested 2 hypotheses: first, that NLR is a prognostic biomarker for overall survival (OS) after curative treatment; second, that NLR is a predictive biomarker for the OS benefit from NAC.
MATERIALS AND METHODS
We conducted this work according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines. 27, 30 This study's REMARK profile is shown in Table 1 .
Patients
We performed a secondary analysis of patients enrolled in SWOG 8710, a multi-institutional, randomized phase 3 trial. Full protocol details have been previously reported. 29 In brief, the trial accrued 317 patients between 1987 and 1998 with T2-T4aN0 transitional cell BC 31 and a SWOG performance status of 0 or 1. Patients were randomly assigned to RC alone or 3 cycles of NAC with methotrexate, vinblastine, doxorubicin, and cisplatin followed by RC. Patients were followed clinically every 6 months after treatment; the most recent vital status update occurred on May 8, 2013. All trial participants gave written informed consent, and all institutions' relevant ethics committees gave study approval. We conducted the current analysis under a data use agreement with SWOG and with approval of the institutional review board of the University of Pennsylvania.
Specimen Characteristics and Assay Methods
The trial protocol required enrolling institutions to obtain pretreatment blood work, including a CBC with differential, within 14 days of patient registration. For the current study, a single investigator who was blinded to clinical outcomes abstracted the CBC data from trial flow sheets. We calculated NLR by dividing the number of neutrophils by the number of lymphocytes.
Study Design
SWOG 8710 was designed to test a therapeutic question and did not contain a planned biomarker endpoint. However, the trial allows for a category B study of NLR. 28 For the current investigation, we developed a prespecified analysis plan before examining the data.
From all SWOG 8710 patients, we identified 2 cohorts, a prognostic cohort and a predictive cohort, to test NLR's value as a biomarker ( Fig. 1) . Prognostic biomarkers give information about cancer outcomes regardless of the specific treatment. 32, 33 Therefore, the prognostic cohort comprised patients with a pretreatment NLR who successfully completed curative therapy (RC with or without NAC). Patients were excluded if they did not complete curative surgery, and we analyzed the cohort according to treatment received. We additionally tested the prognostic value of NLR separately by treatment arm. 34 On the other hand, predictive biomarkers portend differential responses to a particular therapy, 32 which in this case was NAC. The predictive comparison was between the 2 trial arms, and we wished to preserve the benefits of randomization. Therefore, the predictive cohort included any patient with a pretreatment NLR who was assigned to a trial arm (NAC or no NAC); this group was analyzed according to the intentto-treat principle.
We chose OS as the study endpoint because this is an unambiguous outcome with clear clinical significance. It also avoids the analytic challenges associated with cancer-specific survival 35 or other surrogate endpoints. 36, 37 We defined OS from the date of randomization to the date of death from any cause. Patients alive at last follow-up were treated as right-censored, and we calculated the median follow-up using the reverse KaplanMeier method. 38 In addition to NLR, we considered a priori the following candidate variables for inclusion in our models: age (continuous), sex (male vs female), clinical tumor T category (T2 vs T3/T4a), lymphovascular invasion (LVI) on biopsy or transurethral resection of tumor specimen 39, 40 (negative vs positive), and treatment (RC vs NAC followed by RC). We incorporated only pretreatment variables (ie, no surgical pathology information) because our goal was to test NLR as a pretreatment biomarker.
We also calculated the minimally detectable hazard ratio (HR) based on the number of death events in each cohort. For the prognostic analysis, we calculated 80% power to detect a HR of at least 1.11 for mortality with each unit increase in NLR at a 2-sided a (type I error) value of .05. For the predictive analysis, we calculated 80% power to detect a HR of at least 1.09 for the interaction term of NLR and treatment.
Statistical Analysis Methods
NLR was measured as a continuous variable. We excluded a single extreme outlier (NLR 5 31.3; 94% neutrophils and 3% lymphocytes) that was felt to represent an acutely infected patient. We tested the association of NLR with other candidate variables using the Wilcoxon rank-sum or Kruskal-Wallis test as appropriate. We examined the association of each variable with OS using univariable Cox regression models. All variables with P < .2 on the univariable analysis were included in a multivariable Cox regression model. 41 We used the 2-sided Wald test to determine significance.
There were complete data for all variables except for 19 missing LVI values (7.2%). We included these patients in the study, and we addressed missing data via multiple imputation under the assumption that data were missing at random. We additionally performed a sensitivity analysis using only complete cases.
In the regression models, we kept NLR as a continuous variable on its original scale. We checked assumptions of linearity in log hazard by categorizing continuous covariables and plotting coefficient estimates; we also examined a plot of Martingale residuals. We checked assumptions of proportional hazards using plots of scaled Schoenfeld residuals and likelihood ratio tests on interactions between covariables of interest and log time. All statistical analyses were performed with Stata (version 14.0; StataCorp, College Station, Texas).
RESULTS

Baseline Clinical and Marker Characteristics
The flow of patients in the study and the reasons for exclusion are shown in Figure 1 . From 317 patients enrolled in SWOG 8710, 263 patients (83%) and 230 patients (73%) comprised the predictive and prognostic cohorts, respectively. Patient and disease characteristics are detailed in Table 2 . Excluded patients were more likely to have positive or missing LVI values and higher pretreatment NLR (Supporting Tables 1 and 2 [see online supporting information]). There were no other significant differences between included and excluded patients. Baseline NLR was collected a median of 13 days (interquartile range [IQR], 7-21 days) before the first treatment. The NLR distribution was similar in the prognostic and predictive cohorts with median NLR of 2.66 (IQR, 2.01-4.06) and 2.72 (IQR, 2.03-4.17), respectively (Supporting Fig. 1 [see online supporting information]). A higher NLR was associated with positive or missing LVI values in the predictive cohort; NLR was not significantly associated with any other patient or disease characteristic in either cohort (Table 2 ).
Prognostic and Predictive Analyses
During a median follow-up of 18.6 years, there were 172 deaths in the prognostic cohort. NLR was not significantly associated with OS in either univariable (HR, 1.03; 95% confidence interval [CI], 0.97-1.10; P 5 .30) or multivariable analyses (HR, 1.04; 95% CI, 0.98-1.11; P 5 .24; Table  3 and Supporting Fig. 2 [see online supporting information]). In the univariable analysis, age, sex, T category, and treatment showed some association with OS. In the multivariable analysis, both older age (HR, 1.05; 95% CI, 1.04-1.07; P < .001) and treatment with RC alone (HR, 1.39; 95% CI, 1.03-1.88; P 5 .03) remained significantly associated with worse OS (Table 3) . When the prognostic cohort was analyzed separately by treatment arm, NLR was still not significantly associated with OS (Supporting Tables 3 and 4 [see online supporting information]). 34 During a median follow-up of 18.6 years, there were 205 deaths in the predictive cohort. In the multivariable analysis, NLR did not predict for the response to NAC (HR, 1.01; 95% CI, 0.90-1.14; P 5 .86 for the interaction term; Table 4 and Supporting Fig. 3 [see online supporting information]).
Model Assumptions and Sensitivity Analysis
There were no significant deviations from the model assumptions of proportional hazards or linearity. Specifically, the Schoenfeld residuals-based score test did not reject its null hypothesis (prognostic analysis, P 5 .27; 
DISCUSSION
In contrast to previous studies, this analysis found that NLR was not a prognostic biomarker for OS in muscleinvasive BC. Furthermore, NLR was not predictive for the OS benefit from NAC. There are 2 broad interpretations of this study's findings. First, NLR might truly be a prognostic or predictive biomarker, and this study failed to detect the association. Most randomized clinical trials are designed and powered to test a therapeutic question; secondary biomarker analyses may then be underpowered. 28 However, the long-term follow-up and significant mortality in SWOG 8710 generated a meaningful number of OS events. Therefore, our power analyses suggest that any undetected true association between NLR and OS would likely have a limited effect size (HR of less than approximately 1.1 for each unit increase in NLR). The value of such a modest HR would be further reduced by the relatively narrow range of NLR. In summary, it is possible that a small association exists that was not detected in this study, but we would question the practical meaning of such an association. A biomarker must achieve significant differentiation between patients to be clinically useful.
The second interpretation of our findings is that NLR is truly not a prognostic or predictive biomarker in BC. Why then do previous studies suggest otherwise? Perhaps pitfalls in analysis, reporting, and publication have contributed to a literature that is overly enthusiastic about NLR. This would not be unusual: biomarker studies are almost universally positive. For example, an analysis of more than 1900 publications on cancer prognostic markers found that nearly 95% reported positive results. 42 A particular analytic concern in biomarker studies is the use of observational data sets. These are susceptible to biases from a lack of standardized inclusion criteria, treatment schemes, and follow-up schedules. 43 The use of observational data sets can significantly inflate prognostic effect sizes compared to data from clinical trials. 44 Therefore, studies of observational data are classified as category C or D and are placed at the bottom of the biomarker level-of-evidence framework proposed by Simon et al. 28 Notably, all previous studies of NLR in BC analyzed observational data. The current report used prospectively collected clinical trial data and is the first such category B study of NLR in BC. Considerably stronger evidence is generated with this approach. [26] [27] [28] A second analytic issue involves handling of the continuous NLR variable. Dichotomizing this variable is strongly discouraged because of information loss and bias. 27, [45] [46] [47] In fact, certain methods of selecting a cutpoint can raise the false-positive rate to nearly 40%. 48 However, most previous studies dichotomized NLR 13, [17] [18] [19] 21, 23, 24 or did not report effect sizes for the continuous variable. 15 This concern is not limited to studies in BC: a recent global review of NLR across various primary cancers found that 96% of publications dichotomized the variable. 6 In addition to these analytic issues, biases in reporting and publication may also contribute to a surfeit of positive results. 49, 50 Reporting bias includes both selective reporting and poor reporting. 26 An example of selective reporting is a study that analyzes multiple endpoints or fits several multivariable models but reports only those with significant P values. 26, 27 Poor reporting leads to publications with vague or incomplete details, and this makes it difficult for readers to fully appraise the study. These biases can significantly skew the biomarker literature. 51 The REMARK guidelines offer an opportunity to reduce both types of reporting biases; unfortunately, adherence was not optimal in previous NLR studies (Supporting Table 5 [see online supporting information]).
Finally, publication bias occurs when authors do not submit negative studies or editors do not accept them. 49, 52 The former practice, sometimes termed the file-drawer problem, 53 may be a substantial issue in the biomarker literature. 26, 27 This concern is heightened for studies of NLR because CBCs are a ubiquitous laboratory test. How many investigators queried existing databases for an association of NLR with OS and, finding a null result, decided to avoid the trouble of generating a full manuscript? 54 Indeed, meta-analyses suggest that publication bias affects the NLR literature. 6, 55 Together, these various pitfalls may explain why NLR appeared promising in the previous literature but was negative in the current study. Although these pitfalls were minimized in the current analysis, our work has other important limitations that should be emphasized. First, SWOG 8710 did not contain a planned biomarker endpoint; although prospectively collected data were used, the current analysis was retrospective. This also placed limits on the study's power, as discussed previously. Second, the time period during which SWOG 8710 was conducted colors the interpretation of our study. For example, some of the T3 tumors 31 in the trial would now be considered T2 disease, and current guidelines recommend different chemotherapy regimens than the one used in the trial. 56 Finally, we analyzed CBC values from the trial flow sheets instead of raw laboratory data, and this raises the possibility of transcription errors. However, we attempted to address this issue by excluding patients with CBC differentials that did not sum to 100%.
In conclusion, this is the first category B analysis of NLR in BC. In contrast to previous studies, these results suggest that NLR is neither a prognostic biomarker nor a predictive biomarker for OS in muscle-invasive BC.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Seth P. Lerner is a consultant for BioCancell, Vaxxion, UroGen, and Telesta; is an expert advisor for Sitka, Neucleixx, Taris, and Ferring; has received grants from Endo, FKD, Viventia, Roche, Genentech, and Genome Dx; and is coeditor-in-chief for Bladder Cancer. John P. Christodouleas is an employee of Elekta, Inc.
AUTHOR CONTRIBUTIONS
Eric Ojerholm: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing-original draft, and writing-review/editing. Andrew Smith: Data curation, formal analysis, investigation, methodology, resources, software, validation, visualization, and writing-review/editing. Wei-Ting Hwang: Formal analysis, investigation, methodology, resources, software, visualization, and writing-review/editing. Brian C. Baumann: Data curation, formal analysis, investigation, and writing-review/editing. Kai N. Tucker: Data curation, formal analysis, investigation, and writing-review/ editing. Seth P. Lerner: Formal analysis, investigation, resources, and writing-review/editing. Ronac Mamtani: Formal analysis, investigation, and writing-review/editing. Ben Boursi: Formal analysis, investigation, and writing-review/editing. John P. Christodouleas: Conceptualization, formal analysis, investigation, methodology, project administration, resources, supervision, visualization, and writing-review/editing.
